US Stocks Edge Higher as Oil Prices Retreat on Iran Negotiation Hopes Cryptocurrency Market Faces Renewed Volatility as Bitcoin and Ethereum Decline Amid Macroeconomic and Geopolitical Headwinds Global Infrastructure Funding Surges as Japanese Banks Lead FiveYear Doubling Chiyoda Set to Fully Restart Construction on Qatar LNG Expansion Project Why Titan Company Could Lead Indias Formalizing Gold Market Ebola Outbreak in DR Congo Red Cross Casualties Raise Regional Health and Economic Risks IMCC Q1 2026 Earnings Disappointing EPS Amid Limited Disclosure Stock Surges UFCS Q1 2026 Earnings EPS Surges Past Estimates Stock Declines Despite Strong Performance CPIX Q1 2026 Earnings Narrowing Losses and Strategic Progress Amidst Revenue Challenges Block Inc XYZ Q1 2026 Earnings Strong EPS Beat of 2443 Surprises Markets Shares Dip Slightly GDRX Q1 2026 Earnings EPS Misses Estimates Despite Positive Stock Reaction Guggenheim Strategic Opportunities Fund GOF Edges Lower as Key Support Holds MESHW Warrants Hold Steady at 030 Quiet Session for Meshflow Acquisition Corp Rekor Systems REKR Holds at 077 as Minor Decline Tests Support Levels Aurinia Pharmaceuticals AUPH Treads at 1522 as Shares Dip Support and Resistance in Focus Futu Holdings FUTU Surges 17 Breaking Resistance or Nearing Overextension Over OneThird of TwoYear Mutual Fund SIPs Report Losses Market Timing and Sector Selection Matter Arrow Financial Q1 2026 Earnings EPS Beats Estimates by 176 Banco Bradesco BBDO Shares Decline 159 as Resistance Holds Firm Nanobiotix SA NBTX Q4 2025 Earnings Wide EPS Miss Stock Edges Higher on Clinical Progress APPF Q1 2026 Earnings EPS Beats Estimates as Software Provider Navigates Property Management Demand New Pacific Metals Corp NEWP Q1 2026 Earnings EPS Miss Marks Quarter of Operational Progress Amid Narrowing Losses First Citizens BancShares FCNCN Q1 2026 Earnings Strong EPS Beat Amid Stable Preferred Stock Performance PAM Q1 2026 Earnings Stellar Earnings Beat Driven by Exceptional Operational Performance BIP Q1 2026 Earnings Significant EPS Miss Amidst Operational Headwinds Day One Biopharmaceuticals Q4 2025 Earnings EPS Misses Estimates as PreRevenue Biotech Advances Pipeline